NEW YORK (GenomeWeb) – Rheonix today said it received a Small Business Innovation Research Phase I Fast-Track grant to complete the development of its fully automated self-confirming assay for the simultaneous detection of HIV/AIDS antibodies and viral RNA in a single specimen.

The grant from the National Institutes of Health is for six months and $189,646. Ithaca, NY-based Rheonix said it anticipates being awarded a follow-on 18-month, $1.5 million Phase II award.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.